PrimegeGene wins two more invention patent certificates and steadily strengthens its innovation strength.

Recently, PrimegeGene's self-developed invention patents of "a precursor of JAK inhibitor and its preparation and application" and "a diaryl macrocyclic compound, pharmaceutical composition and its use" have been successfully authorized by the State Intellectual Property Office of China (SIPO) and the Japan Patent Office (JPO) and have obtained the invention patent certificates respectively. The two patents were successfully authorized by the State Intellectual Property Office and the Japan Patent Office respectively, and obtained the invention patent certificates. This is another breakthrough in PrimegeGene's innovation in the field of biopharmaceuticals, marking a further enrichment of PrimegeGene's product pipeline and a new level of new drug research and development.

Since its establishment, PrimegeGene has been focusing on pharmaceutical innovation, increasing its investment in technological innovation and R&D, and continuously improving its independent R&D and innovation capabilities. In addition, PQI Pharma has been actively applying for patents globally to provide intellectual property protection for innovative drug discovery and development. PrimegeGene's good innovation mechanism has strongly promoted the continuous output of innovative achievements, and the company's R&D and innovation strength has been steadily increasing.